Barron's
http://online.barrons.com/public/mainBarron's Magazine is a weekly financial newspaper that covers US financial information, market developments, and relevant statistics. Each issue provides a summary of the previous week's market activity, news reports, and an outlook on the week to come. The paper has been published since 1921 by Dow Jones & Company, the publisher of The Wall Street Journal. The paper is named after Clarence W. Barron who is considered the founder of financial journalism.
-
Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant
-
Vir Biotechnology Inc. (VIR) and GlaxoSmithKline's (GSK) Sotrovimab Retains Activity Against Key Omicron Mutations, per Preclinical Data
-
Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant
-
Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant
-
GSK (GSK) and Vir Biotechnology (VIR) Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment
-
GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment
-
GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment
-
Vir Biotechnology Inc. (VIR) and GlaxoSmithKline (GSK) Phase 3 Trial of sotrovimab for Early Treatment of COVID-19 Met Primary Endpoint
-
Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
-
Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
-
GSK (GSK), Vir Biotechnology (VIR) Confirms FDA Emergency Use Authorization for COVID Treatment Sotrovimab
-
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients
-
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients
-
Eli Lilly & Co. (LLY), Vir Biotech (VIR) & GlaxoSmithKline (GSK) Report Positive Topline Data from Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
-
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
-
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
-
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
-
Vir Biotechnology (VIR) Gains 50% as VIR-7831 Reduces Hospitalization and Risk of Death from COVID-19
-
Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19
-
Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19
-
Vir Biotechnology Inc. (VIR), GlaxoSmithKline (GSK) Expand Coronavirus Collaboration
-
GSK and Vir Biotechnology Expand Coronavirus Collaboration to Advance New Therapeutics for Influenza and Other Respiratory Viruses
-
GSK and Vir Biotechnology Expand Coronavirus Collaboration to Advance New Therapeutics for Influenza and Other Respiratory Viruses
-
Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
-
Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
-
Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
-
Vir Biotechnology Inc. (VIR), GlaxoSmithKline plc (GSK) Report NHS-Supported AGILE Study to Evaluate VIR-7832 in Early Treatment of COVID-19
-
Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
-
Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
-
Vir Biotechnology (VIR)and GSK (GSK) Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
-
Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
-
Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
-
Vir Biotechnology Inc. (VIR), GSK (GSK) announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for treatment of COVID-19
-
Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19
-
Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19
-
Vir Biotechnology Inc. (VIR), GlaxoSmithKline (GSK) Begin Phase 2/3 Study of COVID-19 Antibody Treatment
-
Vir Biotechnology and GSK Start Phase 2/3 Study of COVID-19 Antibody Treatment
-
Vir Biotechnology and GSK Start Phase 2/3 Study of COVID-19 Antibody Treatment
-
Vir Biotechnology Inc. (VIR), GlaxoSmithKline (GSK) Enter Collaboration on Coronavirus; GSK to Make $250M Equity Investment at $37.73
-
GSK and Vir Biotechnology enter collaboration to find coronavirus solutions
-
GSK and Vir Biotechnology enter collaboration to find coronavirus solutions
